Evidence map›Paper›PMID 37779602›Full record

ArticleCardiovascular endocrinology & metabolism2023

The concomitant use of sodium-glucose co-transporter 2 inhibitors improved the renal outcome of Japanese patients with type 2 diabetes treated with glucagon-like peptide 1 receptor agonists.

Kazuo Kobayashi, Masao Toyoda, Nobuo Hatori, Shunichiro Tsukamoto, Moritsugu Kimura, Hiroyuki Sakai, Takayuki Furuki, Keiichi Chin, Tomohiko Kanaoka, Togo Aoyama and 17 more

Open access · diamondAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Cardiovascular endocrinology & metabolism, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.4field-weighted citation impact, top 33% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 2 citations in OpenAlex.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

27 authors at 4 institutions in 1 country.

Kazuo KobayashiCommittee of Hypertension and Kidney Disease, Kanagawa Physicians Association.
Masao ToyodaDivision of Nephrology, Endocrinology and Metabolism, Department of Internal Medicine, Tokai University School of Medicine, lsehara.
Nobuo HatoriCommittee of Hypertension and Kidney Disease, Kanagawa Physicians Association.
Shunichiro TsukamotoDepartment of Medical Science and Cardiorenal Medicine, Yokohama City University Graduate School of Medicine, Yokohama.
Moritsugu KimuraDivision of Nephrology, Endocrinology and Metabolism, Department of Internal Medicine, Tokai University School of Medicine, lsehara.
Hiroyuki SakaiCommittee of Hypertension and Kidney Disease, Kanagawa Physicians Association.
Takayuki FurukiCommittee of Hypertension and Kidney Disease, Kanagawa Physicians Association.
Keiichi ChinCommittee of Hypertension and Kidney Disease, Kanagawa Physicians Association.
Tomohiko KanaokaDepartment of Medical Science and Cardiorenal Medicine, Yokohama City University Graduate School of Medicine, Yokohama.
Togo AoyamaDivision of Nephrology, Department of internal medicine, Kitasato University School of Medicine, Sagamihara.
Tomoya UmezonoCommittee of Hypertension and Kidney Disease, Kanagawa Physicians Association.
Shun ItoCommittee of Hypertension and Kidney Disease, Kanagawa Physicians Association.
Daisuke SuzukiCommittee of Hypertension and Kidney Disease, Kanagawa Physicians Association.
Hiroshi TakedaCommittee of Hypertension and Kidney Disease, Kanagawa Physicians Association.
Hisakazu DegawaCommittee of Hypertension and Kidney Disease, Kanagawa Physicians Association.
Toshimasa HishikiCommittee of Hypertension and Kidney Disease, Kanagawa Physicians Association.
Hidetoshi ShimuraCommittee of Hypertension and Kidney Disease, Kanagawa Physicians Association.
Shinichi NakajimaCommittee of Hypertension and Kidney Disease, Kanagawa Physicians Association.
Masaaki MiyauchiCommittee of Hypertension and Kidney Disease, Kanagawa Physicians Association.
Hareaki YamamotoCommittee of Hypertension and Kidney Disease, Kanagawa Physicians Association.
Yutaka HatoriCommittee of Hypertension and Kidney Disease, Kanagawa Physicians Association.
Masahiro HayashiCommittee of Hypertension and Kidney Disease, Kanagawa Physicians Association.
Kazuyoshi SatoCommittee of Hypertension and Kidney Disease, Kanagawa Physicians Association.
Masaaki MiyakawaCommittee of Hypertension and Kidney Disease, Kanagawa Physicians Association.
Yasuo TerauchiDepartment of Endocrinology and Metabolism, Yokohama City University Graduate School of Medicine, Yokohama, Japan.
Kouichi TamuraDepartment of Medical Science and Cardiorenal Medicine, Yokohama City University Graduate School of Medicine, Yokohama.
Akira KanamoriCommittee of Hypertension and Kidney Disease, Kanagawa Physicians Association.
Kanagawa Prefecture Medical Association · JPYokohama City University · JPTokai University · JPKitasato University · JP

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Aims: This study aimed to clarify the renal influence of glucagon-like peptide 1 receptor agonists (GLP1Ras) with or without sodium-glucose co-transporter 2 inhibitors (SGLT2is) on Japanese patients with type 2 diabetes mellitus (T2DM). Methods: We retrospectively extracted 547 patients with T2DM who visited the clinics of members of Kanagawa Physicians Association. The progression of albuminuria status and/or a ≥ 15% decrease in the estimated glomerular filtration rate (eGFR) per year was set as the renal composite outcome. Propensity score matching was performed to compare GLP1Ra-treated patients with and without SGLT2i. Results: After matching, 186 patients in each group were compared. There was no significant difference of the incidence of the renal composite outcomes (17% vs. 20%, Conclusion: The concomitant use of SGLT2i with GLP1Ra improved the annual decrease in the eGFR and the urine albumin-to-creatinine ratio in Japanese patients with T2DM.

Indexed as

glucagonglucose co-transporter 2 inhibitorslike peptide 1 receptor agonistrenal outcomesodium

Identifiers

PMID37779602
PMCPMC10540913
OpenAlexW4387173529

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.